Lower atovaquone/proguanil concentrations in patients taking efavirenz, lopinavir/ritonavir or atazanavir/ritonavir

M van Luin; Marchina Ende; C Richter; Martje Visser; D Faraj; A van de Ven; Luc Gelinck; F Kroon; FW Wit; Ron van Schaik; PFM Kuks; DM Burger

doi:10.1097/QAD.0b013e3283389129

Lower atovaquone/proguanil concentrations in patients taking efavirenz, lopinavir/ritonavir or atazanavir/ritonavir

M van Luin
, Marchina Ende
, C Richter
, Martje Visser
, D Faraj
, A van de Ven
, Luc Gelinck
, F Kroon
, FW Wit
, Ron van Schaik
, PFM Kuks
, DM Burger

External organisation

Research output: Contribution to journal › Article › Academic › peer-review

38 Citations (Scopus)

Abstract

HIV-infected travellers frequently use atovaquone/ proguanil as malaria prophylaxis. We compared atovaquone/ proguanil pharmacokinetics between healthy volunteers and HIV-infected patients taking efavirenz, lopinavir/ ritonavir or atazanavir/ritonavir. The geometric mean ratio (95% confidence interval) area under the curve (AUC)(0 -> t) for atovaquone relative to the healthy volunteers was 0.25 (0.16-0.38), 0.26 (0.17-0.41) and 0.54 (0.350.83) for patients on efavirenz, lopinavir/ ritonavir and atazanavir/ ritonavir, respectively. Proguanil plasma concentrations were also significantly lower (38-43%). Physicians should be alert for atovaquone/ proguanil prophylaxis failures in patients taking efavirenz, lopinavir/ ritonavir or atazanavir/ ritonavir.

Original language	Undefined/Unknown
Pages (from-to)	1223-1226
Number of pages	4
Journal	AIDS
Volume	24
Issue number	8
DOIs	https://doi.org/10.1097/QAD.0b013e3283389129
Publication status	Published - 2010

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Research programs

EMC MM-01-25-01
EMC MM-04-28-04

Access to Document

10.1097/QAD.0b013e3283389129

http://hdl.handle.net/1765/27864

Cite this

@article{3a349a4dc17c43958bfa24ef6a94fabd,

title = "Lower atovaquone/proguanil concentrations in patients taking efavirenz, lopinavir/ritonavir or atazanavir/ritonavir",

abstract = "HIV-infected travellers frequently use atovaquone/ proguanil as malaria prophylaxis. We compared atovaquone/ proguanil pharmacokinetics between healthy volunteers and HIV-infected patients taking efavirenz, lopinavir/ ritonavir or atazanavir/ritonavir. The geometric mean ratio (95\% confidence interval) area under the curve (AUC)(0 -> t) for atovaquone relative to the healthy volunteers was 0.25 (0.16-0.38), 0.26 (0.17-0.41) and 0.54 (0.350.83) for patients on efavirenz, lopinavir/ ritonavir and atazanavir/ ritonavir, respectively. Proguanil plasma concentrations were also significantly lower (38-43\%). Physicians should be alert for atovaquone/ proguanil prophylaxis failures in patients taking efavirenz, lopinavir/ ritonavir or atazanavir/ ritonavir.",

author = "\{van Luin\}, M and Marchina Ende and C Richter and Martje Visser and D Faraj and \{van de Ven\}, A and Luc Gelinck and F Kroon and FW Wit and \{van Schaik\}, Ron and PFM Kuks and DM Burger",

year = "2010",

doi = "10.1097/QAD.0b013e3283389129",

language = "Undefined/Unknown",

volume = "24",

pages = "1223--1226",

journal = "AIDS",

issn = "0269-9370",

publisher = "Lippincott Williams \& Wilkins",

number = "8",

}

TY - JOUR

T1 - Lower atovaquone/proguanil concentrations in patients taking efavirenz, lopinavir/ritonavir or atazanavir/ritonavir

AU - van Luin, M

AU - Ende, Marchina

AU - Richter, C

AU - Visser, Martje

AU - Faraj, D

AU - van de Ven, A

AU - Gelinck, Luc

AU - Kroon, F

AU - Wit, FW

AU - van Schaik, Ron

AU - Kuks, PFM

AU - Burger, DM

PY - 2010

Y1 - 2010

N2 - HIV-infected travellers frequently use atovaquone/ proguanil as malaria prophylaxis. We compared atovaquone/ proguanil pharmacokinetics between healthy volunteers and HIV-infected patients taking efavirenz, lopinavir/ ritonavir or atazanavir/ritonavir. The geometric mean ratio (95% confidence interval) area under the curve (AUC)(0 -> t) for atovaquone relative to the healthy volunteers was 0.25 (0.16-0.38), 0.26 (0.17-0.41) and 0.54 (0.350.83) for patients on efavirenz, lopinavir/ ritonavir and atazanavir/ ritonavir, respectively. Proguanil plasma concentrations were also significantly lower (38-43%). Physicians should be alert for atovaquone/ proguanil prophylaxis failures in patients taking efavirenz, lopinavir/ ritonavir or atazanavir/ ritonavir.

AB - HIV-infected travellers frequently use atovaquone/ proguanil as malaria prophylaxis. We compared atovaquone/ proguanil pharmacokinetics between healthy volunteers and HIV-infected patients taking efavirenz, lopinavir/ ritonavir or atazanavir/ritonavir. The geometric mean ratio (95% confidence interval) area under the curve (AUC)(0 -> t) for atovaquone relative to the healthy volunteers was 0.25 (0.16-0.38), 0.26 (0.17-0.41) and 0.54 (0.350.83) for patients on efavirenz, lopinavir/ ritonavir and atazanavir/ ritonavir, respectively. Proguanil plasma concentrations were also significantly lower (38-43%). Physicians should be alert for atovaquone/ proguanil prophylaxis failures in patients taking efavirenz, lopinavir/ ritonavir or atazanavir/ ritonavir.

U2 - 10.1097/QAD.0b013e3283389129

DO - 10.1097/QAD.0b013e3283389129

M3 - Article

C2 - 20299957

SN - 0269-9370

VL - 24

SP - 1223

EP - 1226

JO - AIDS

JF - AIDS

IS - 8

ER -